孟鲁司特钠片辅助治疗支气管哮喘急性发作的可行性及安全性研究

The feasibility and safety of the Montelukast Sodium adjuvant treatment on acute attack of bronchial asthma

目的探讨孟鲁司特钠片辅助治疗支气管哮喘急性发作的临床疗效。方法选取我院2014年10月~2015年10月收治的支气管哮喘急性发作患者共80例,按照入院时间顺序随机分为对照组(n=40)与观察组(n=40),对照组患者接受甲泼尼龙琥珀酸钠治疗,观察组在此基础上给予孟鲁司特钠片的辅助治疗,比较两组患者支气管哮喘缓解情况、临床症状体征消失时间、肺功能及不良反应。结果观察组治疗总有效率为87.5%,明显高于对照组67.5%(x^2=4.5878,P<0.05)。观察组咳嗽、气喘、胸闷及肺部湿啰音消失时间均明显短于对照组(t=14.1608,8.1706,13.8506,10.4794,P<0.05)。两组患者治疗前肺功能指标无明显差异(P>0.05)。治疗后,观察组患者肺功能FVC、PEF%与FEV1/PEF%均高于对照组,差异有统计学意义(t=-5.7429,-43.4516,-35.2151,P<0.05)。观察组不良反应发生率为5.0%,与对照组不良反应发生率7.5%相比,无明显统计学差异(x^2=0.2133,P>0.05)。结论孟鲁司特钠片辅助治疗支气管哮喘急性发作有较好的临床效果,能缩短病程,且安全性高,值得临床推广应用。

Objective To explore the clinical effect of the Montelukast Sodium adjuvant treatment on acute attack of bronchial asthma. Methods A total of 80 patients with bronchial asthma acute attack in our hospital from October 2014 to October 2015 were selected, all patients were randomly divided into the control group（n=40） and the observation group（n=40） according to the order of admission time. The control group received methylprednisolone sodium succinate treatment, the observation group was given Montelukast Sodium adjuvant treatment.The bronchial asthma remission condition, clinical symptoms and signs disappeared time,pulmonary function and adverse reactions were compared between two groups. Results The total effective rate of the observation group was 87.5%, significantly higher than the 67.5% of control group（x^2=4.5878,P〈0.05）. cough, asthma, chest tightness and lung wet rales disappearance time in observation group were significantly shorter than that of the control group（t=14.1608, 8.1706, 13.8506, 10.47694, P〈0.05）. There was no significant difference in pulmonary function index between the two groups before treatment（P〉0.05）. After treatment, the pulmonary function FVC, PEF% and FEV1/PEF% in observation group were higher than that of control group, the difference was statistically significant（t=-5.7429,-43.4516,-35.2151, P〈0.05）.The incidence of adverse reactions in observation group was 5.0%, and the incidence of adverse reactions in the control group was 7.5%, there was no obvious difference between the two groups（x^2=0.2133,P〉0.05）. Conclusion The clinical effect of Montelukast Sodium adjuvant treatment of acute attack of bronchial asthma has good clinical effect, can shorten the course of disease, and the safety is high, it is worthy of clinical popularization and application.